Our obsession with gene expression, landed us into cancer since cancers are gene expression kaleidoscopes and a beautiful system to explore RNA elasticity. In the context of cancer, there are a few unsolved paradigms that interest us the most. One of those is how to recognize all phenotypes of Circulating Tumour Cells that float around in peripheral blood (JCM 2020) (bioRxiv 2021). As we know cancer cells undergo molecular remodeling to successfully traverse distant organs. Only a fraction of such disguising strategies is known to us. One is Epithelial to Mesenchymal Transition or EMT. Current best practice methods are limited to selection for size or canonical markers such as EpCAM. We use a unique combination of unbiased, microfluidic enrichment of CTCs and gene expression pattern recognition to detect CTCs irrespective of any specific marker. Along similar lines, we developed and commercialized the Tumour Educated Platelet (TEP) gene panel for early cancer detection (BMC Genomics 2021) (CareOnco). More recently we interrogated NK-Cancer cell interaction at doublet resolution and learned signatures associated with killing by NKs. Notably, not every NK cell kills every cancer cell that comes in its contact. A different ongoing study alludes to single cell-based signatures that are associated with clonal advantage within a tumor ecosystem. Watch out for future developments.